APOE and Alzheimer disease: Although studies using bexarotene have led to mixed results on amyloid and Aβ levels in AD mice [51–56], the emerging consensus is that increasing apoE lipidation via LXR or RXR agonists provides therapeutic benefits in mice, even in the case of apoE4.